Psychotropic polypharmacy for the treatment of bipolar disorder in Taiwan

Psychiatric Services

Volumn 65, Issue 1, 2014, Pages 125-128

  Hung, Galen Chin Lun ^a   Yang, Shu Yu ^a,b   Chen, Yuefan ^d   Lin, Shih Ku ^a,c  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; STABILIZING AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYPHARMACY; PRESCRIPTION; TAIWAN; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; PSYCHOTROPIC DRUGS; TAIWAN;

EID: 84892384168     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201200529     Document Type: Article

References (15)

1. Drugs@FDA. Silver Spring, Md, US Food and Drug Administration. Accessed July 31, 2012. Available at www.accessdata.fda.gov/scripts/cder/drugsatfda
2. Baldessarini R, Henk H, Sklar A, et al: Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatric Services 59:1175-1183, 2008
3. Alda M, Yatham LN: Is monotherapy as good as polypharmacy in long-term treatment of bipolar disorder? Canadian Journal of Psychiatry 54:719-725, 2009
4. Correll CU, Frederickson AM, Kane JM, et al: Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disorders 10:788-797, 2008
5. Grunze H, Vieta E, Goodwin GM, et al: The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World Journal of Biological Psychiatry 10:85- 116, 2009
6. Yatham LN, Kennedy SH, Schaffer A, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders 11:225-255, 2009
7. Sachs GS, Thase ME, Otto MW, et al: Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry 53:1028-1042, 2003
8. Moreno C, Laje G, Blanco C, et al: National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Archives of General Psychiatry 64: 1032-1039, 2007
9. Depp C, Ojeda VD, Mastin W, et al: Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001-2004. Psychiatric Services 59:1169-1174, 2008
10. Mojtabai R, Olfson M: National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry 67:26-36, 2010
11. Frye MA, Ketter TA, Leverich GS, et al: The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. Journal of Clinical Psychiatry 61: 9-15, 2000
12. Biancosino B, Barbui C, Marmai L, et al: Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. International Clinical Psychopharmacology 20:305-309, 2005
13. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway, WHO Collaborating Centre for Drug Statistic Methodology, 2003
14. Dennehy EB, Bauer MS, Perlis RH, et al: Concordance with treatment guidelines for bipolar disorder: data from the systematic treatment enhancement program for bipolar disorder. Psychopharmacology Bulletin 40:72-84, 2007
15. Preskorn SH, Lacey RL: Polypharmacy: when is it rational? Journal of Psychiatric Practice 13:97-105, 2007